ReviewEuropean journal of medical research2011
Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.
Review in European journal of medical research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 145 citations in OpenAlex.
- Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis.Antimicrobial agents and chemotherapy · 2013Trial
- Cryo-EM structures of Candida albicans chitin synthase Chs1 reveal a druggable translocation channel.Nature microbiology · 2026Article
- Clinical Outcomes of Micafungin and Anidulafungin inJournal of fungi (Basel, Switzerland) · 2026Article
- Ethanolic extract of Polish Propolis exhibits synergy with selected antifungal agents against yeast pathogens causing candidiasis.Scientific reports · 2026Article
- Repurposing caspofungin as a small-molecule inhibitor of Clostridium perfringens α-toxin for treatment of gas gangrene.Communications medicine · 2026Article
- Comparative real-world safety profiles of caspofungin, micafungin, and anidulafungin: a disproportionality analysis based on FAERS and VigiAccess databases.Frontiers in pharmacology · 2026Article
- Ultrastructural and Immunohistochemical Study on the Nephrotoxicity Following Intravitreal Administration of the Antifungal Agents Voriconazole and Micafungin in New Zealand White Rabbits.International journal of molecular sciences · 2025Article
- FDA-Approved Antibacterials and Echinocandins.Antibiotics (Basel, Switzerland) · 2025Review
- The fluoroquinolone compounds potentiate the antifungal activity of the echinocandins against Aspergillus fumigatus.Bioscience reports · 2025Article
- Perspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit.Antibiotics (Basel, Switzerland) · 2024Review
- Safety and efficacy of non-reduced use of caspofungin in patients with Child-Pugh B or C cirrhosis: a real-world study.Infection · 2024Article
- A novel liposomal formulation for ocular delivery of caspofungin: an experimental study by quality by design-based approach.Therapeutic delivery · 2024Article
- Tacrolimus and Cyclosporin Pharmacotherapy, Detection Methods, Cytochrome P450 Enzymes after Heart Transplantation.Cardiovascular & hematological agents in medicinal chemistry · 2024Review
- Progress in the application of nanoparticles for the treatment of fungal infections: A review.Mycology · 2024Review
- The cyclic lipopeptide micafungin induces rupture of isolated mitochondria by reprograming the mitochondrial inner membrane anion channel.Mitochondrion · 2023Article
- Cyclic Peptides with Antifungal Properties Derived from Bacteria, Fungi, Plants, and Synthetic Sources.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2023Review
- Natural and Man-Made Cyclic Peptide-Based Antibiotics.Antibiotics (Basel, Switzerland) · 2022Review
- Echinocandins - structure, mechanism of action and use in antifungal therapy.Journal of enzyme inhibition and medicinal chemistry · 2022Review
- Meyerozyma guilliermondii species complex: review of current epidemiology, antifungal resistance, and mechanisms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Echinocandins represent the newest class of antifungal agents. Currently, three echinocandins, anidulafungin, caspofungin and micafungin are licensed for clinical use in various indications. They act as inhibitors of β-(1,3)-glucan synthesis in the fungal cell wall and have a favorable pharmacological profile. They have a broad spectrum of activity against all Candida species. Higher MIC's have been observed against C. parapsilosis and C. guilliermondii. Data from clinical trials for invasive Candida infections / candidaemia suggest that the clinical outcome of patients treated with either drug may be very similar. A comparison has been done between caspofungin and micafungin but for anidulafungin a comparative trial with another echinocandin is still lacking. All three drugs are highly effective if not superior to treatment with either fluconazole or Amphotericin B, particularly in well-defined clinical settings such as invasive Candida infections, Candida oesophagitis and candidaemia. Differences between the three echinocandins with regard to the route of metabolism, requirement for a loading dose, dose adjustment in patients with moderate to severe hepatic disease and different dosing schedules for different types of Candida infections have to be considered. Relevant drug-drug interactions of Caspofungin and Micafungin are minimal. Anidulafungin has no significant drug interactions at all. However, echinocandins are available only for intravenous use. All three agents have an excellent safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.